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Abstract: Background: Colorectal cancer (CRC) is a leading cause of mortality worldwide and in the
UK. Surgical resection is the main curative treatment modality available and using a laparoscopic
vs. an open approach may have a direct influence on the inflammatory response, influencing
cancer biology and potentially the recurrence kinetics by promoting cancer growth. Methods: This
systematic review aims to compare laparoscopic with open surgery for the treatment of colon cancer
with a specific focus on the moment of the recurrence. We included randomised controlled trials in
intended curative surgery for colon cancer in adults. Interventions: Studies investigating laparoscopic
vs. open resection as an intended curative treatment for patients with confirmed carcinoma of the
colon. The two co-primary outcomes were the time to recurrence and the overall survival (OS)
and disease-free survival (DFS) at three and five years. Meta-analyses were done on the mean
differences. Results: After selection, we reviewed ten randomised controlled trials. Most of the
trials did not display a statistically significant difference in either DFS or OS at three or at five years
when comparing laparoscopic to open surgery. Groups did not differ for the OS and DFS, especially
regarding the time needed to observe the median recurrence rate. The quality of evidence (GRADE)
was moderate to very low. Conclusion: We observed no difference in the recurrence kinetics, OS or
DFS at three or five years when comparing laparoscopic to open surgery in colon cancer.
Keywords: recurrence kinetics; laparoscopic surgery; open surgery; colon cancer; meta-analysis
1. Introduction
Colorectal cancer (CRC) is defined as cancer arising from the epithelium of the colon
or rectum [1]. According to Cancer Research UK [2], it is the 4th most common cancer in
the UK, constituting 11% of all new cancer diagnoses. It is also the second most common
cause of cancer mortality in the UK. Survival is linked to stage at presentation: with early
disease detection associated with better outcomes [3].
CRC is thought to have a multifactorial aetiology, with genetic factors, environmental
exposures (diet, smoking and alcohol intake) and inflammatory conditions being imple-
mented in its development [4]. Among the inflammatory condition, surgery is a scheduled
one, and the reaction of tissue injury might be dependent on modifiable factors, like the
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surgical approach. Indeed, surgery is the most common treatment offered and sometimes
considered to be the only curative modality [4]. Resection is often performed to remove the
primary tumour [5] and can be done using different techniques, ranging from hemicolec-
tomy, where one half of the colon is removed, to total colectomy, where the entire colon
is removed [6]. Resection can be performed using different approaches, namely open or
through a minimally invasive technique [7]. The open approach is the conventional method,
but it is associated with more postoperative pain, a longer hospital stay and, importantly, a
bigger inflammatory response which could, in turn, influence negatively the recurrence
kinetics by promoting cancer growth [8]. In this context, separating the colon from rectal
surgery is relevant. The disease is not only different in the rectum (treated with different
neoadjuvant therapies for colon cancer), but the surgical approaches are also different.
Laparoscopic hemicolectomy is a very different procedure from previous laparoscopic
resections, but also includes specific challenges (and their inflammatory complications)
with the rectum being in the pelvis.
Aims and Objectives
Many systematic reviews do not distinguish between colon and rectal cancer, with
little specific data on colon cancer. This paper aims to conduct a systematic review with
meta-analysis, using available literature on randomised controlled trials (RCTs) across
multiple databases, to compare the effectiveness of laparoscopic versus open surgery for
the intended curative resection of colon cancer in adults. The primary outcomes analysed
are overall survival (OS) and disease-free survival (DFS) at both three and five years. The
secondary objective is the comparison of the time to median recurrence rate.
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
We established the inclusion and exclusion criteria using the PICOS tool [9], which
aided to focus our question. Table 1 summarises the research criteria.
Table 1. Inclusion and exclusion criteria used in the literature search.




Intervention Intended curative laparoscopicsurgery of primary tumour
Control









Study Design Randomised controlled trialspublished in English All other study types
2.2. Search Strategy
We conducted literature search on Ovid MedLine, Ovid Embase, Cochrane Central
Register of Controlled Trials and PubMed. Supplementary S1 reflects the search terms,
combinations and applied limits used.
Two investigators assessed independently each database and compared the screening.
This helped to ensure consistency and eradicate possible bias. After initial screening and
removal of duplicates we compiled a final list of publications for review, as displayed in
Figure 1. This search methodology is based on the PRISMA (Preferred Reporting Items of
Systematic reviews and Meta-Analyses) flowchart.
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Figure 1. Flow diagram displaying literature search protocol. Adapted from PRISMA 2009
flow diagram [10].
2.3. Data Collection and Analysis
Two independent investigators extracted data from selected articles [11–20] and
the research group verified it by using an independent y created data extraction form
(Supplementary S2). In one case we found a s cond publication from the same trial con-
cerning colorectal cancer being publi hed incl ding only data for left colon a cer. When
it was not possible to obtain the raw data from the authors, we extracted data from the
figures using GetData Digitizer software V 2.26.0.20 (GetData Graph digitizer software
version 2.25) assuming a normal distribution for the data [21] to perform the meta-analysis.
We verified the accuracy and the precision of the tool across the graphs used and found the
worst result of +/−0.69% in Tung et al. [11].
We performed a group discussion to resolve discrepancies and compile data. To
determine the quality of evidence extracted from all included studies for which p-values
were available we used the GRADE approach [22]. As all studies were RCTs, the evidence
in all cases was initially deemed ‘high quality’. For serious limitations in study design or
risk of bias we downgraded the quality of evidence by one level (or by two for very serious).
In case of unexplained inconsistency, indirectness of evidence, imprecision of results or
high probability of publication bias, we downgraded evidence by a further level [23].
We compared the mean survival and disease-free periods between groups. We com-
puted quartiles and calculated the interquartile range. The interquartile range (IQR) divided
by 1.35 is a robust measure that describes statistic dispersion and can serve as a surrogate
of standard deviation [24].
We performed a meta-analysis for comparison of means for continuous data using
RevMan V. 5.4.1 software (Cochrance Collaboration, Copenhagen, Denmark). Given the
heterogeneity of studies we used the random effect method.
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2.4. Critical Appraisal
Two independent reviewers performed a critical appraisal for each paper, using a
checklist developed by Scottish Intercollegiate Guidelines Network (SIGN) [25], to evaluate
the validity of RCTs and their results. All members performed an appraisal at least twice.
Table S1 shows the characteristics of each study.
3. Results
3.1. Study Characteristics
The literature search produced 1990 articles. Following title and abstract screening
and full-text review, with inclusion and exclusion criteria applied, we identified a total
of ten RCTs [11–20] for inclusion. No trial carried out any blinding procedure due to the
nature of the surgical procedures. Three trials were multi-centre [15,16,19], and seven
single-centre [11–14,17,18,20]. Analysis involved in total 3610 colon cancer patients. To-
tal of 1808 patients underwent laparoscopic surgery and 1802 underwent conventional
open surgery for intended curative resection of a primary tumour. Three trials [15,16,19]
assessed the non-inferiority of laparoscopic compared to open resection, the remaining
seven trials [11–14,17,18,20] aimed to assess superiority. Almost all studies included data
on both DFS and OS; the exception being Chung et al. [14] that measured only OS.
3.2. Population
All selected studies investigated laparoscopic vs. open resection as an intended cura-
tive treatment for patients with confirmed carcinoma of the colon. The age ranges for par-
ticipants included: no limit [18], ≥18 years [11–15,19], ≥20 years [16,20] and ≥75 years [17].
Table 2 summarises the differences in tumour location. Stage of colon cancer differed
between individuals in all studies and ranged from T0 to T4. However, separation of
outcomes for each stage was beyond the scope of this review. Recurrent exclusion factors
that we included were metastatic disease, pregnant or lactating women and patients con-
sidered unfit for surgery. The conduction of RCTs involved many countries, including
Hong Kong, Japan, the USA and several European countries. All studies involved surgeons
with adequate training to perform laparoscopic surgery.
3.3. Intervention
All included studies in this review assessed the use of non-robotic, laparoscopic resec-
tion of the colon with curative intent, with Chung et al. [14] using a hand-assisted technique.
The only study to use a co-intervention was Tung et al., [11] who assessed the efficacy of
endoscopically inserted, metal stents prior to laparoscopic resection of cancer obstructing
the left colon. Nine studies [11–17,19,20] reported the use of adjuvant chemotherapy in
a proportion of participants. The chemotherapy agent varied between studies and in-
cluded oral 5-fluorouracil derivatives, [16,17] leucovorin, [16] FOLFOX regimen [12,13],
fluoropyrimidine [20] and un-specified regimens [11,14,15]. The proportion of patients
receiving chemotherapy was balanced in intervention and comparator groups [19] in all
studies. Three trials [15,16,20] specified that adjuvant chemotherapy was administered
in stage III patients. Two studies [14,18] reported only on right laparoscopic hemicolec-
tomy and one [13] reported only on left laparoscopic hemicolectomy. The remainder of
the studies [11,15–17,19,20] included patients with varying tumour locations, which in
turn governed the resection site. Toritani et al. [20] was the only study to report the use
of complete mesocolic excision. Lymph node harvesting occurred during laparoscopic
surgery in all studies.
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Table 2. Summary of population characteristics. The only data available are as follows and apply to both colon and rectal cancer patients: in the laparoscopic surgery group, 54 patients
were <80 years and 44 were ≥80 years. For open surgery, 53 were <80 years and 39 were ≥80 years.
Study Intervention Control Population
Average Age (Year) Sample Size Analysed Male Sex (%)
Laparoscopic Open Resection Laparoscopic Open Resection Laparoscopic Open Resection 95% CI
Braga et al., 2005 Laparoscopic surgery Open surgery ≥18 yearsColorectal cancer 65 (13) mean (SD) 67 (11) mean (SD) 190 201 60 60 −14.70 [−18.04,−11.36]
Braga et al., 2010 Laparoscopic surgery Open surgery ≥18 yearsCarcinoma of left colon 62.9
† 64.9 † 78 89 51 † 53 †
Chung et al., 2007 Hand-assisted laparoscopic colectomy Open colectomy ≥18 yearsCarcinoma of cecum or ascending colon 71 72.5 41 40 61 65 21.00 [6.42,35.58]
COLOR, 2009 Laparoscopic surgery Open resection
≥18 years
Carcinoma of caecum, ascending colon,
descending colon or sigmoid colon
71 71 534 542 52 53 −5.80 [−9.56,−2.04]
COST, 2007 Laparoscopically assisted colectomy Open colectomy ≥18 yearsCarcinoma of right, left or sigmoid colon 70 69 435 428 51 49 3.90 [−1.66,9.46]




Adenocarcinoma of colon and rectum NI NI 69 63 50 60 −5.60 [−13.52,2.32]
JCOG404, 2017 Laparoscopic surgery Open surgery
20–75 years
Carcinoma of caecum, ascending colon,
sigmoid colon
64 64 525 520 54 60 4.90 [0.64,9.16]




carcinomas of caecum, ascending colon,
hepatic flexure or transverse colon
68 68 71 74 46 43 −14.80 [−41.27,11.67]
Toritani et al., 2019 Laparoscopic surgery Conventional opensurgery
≥20 years
Transverse and descending colon cancer 64 67 33 33 73 48
Tung et al., 2013 Endolaparoscopic resection Conventional opensurgery
≥18 years
Obstructed left sided colon cancer. 64.5 68.5 22 13 58 50 −1.30 [−17.69,15.09]
Data for colon and rectal cancer combined, as paper did not separate these two groups. † Data for cancer and non-cancer patients combined, as paper did non separate these two groups. ‡ Authors were
contacted to confirm that all the participants were over 18 years old in accordance with the inclusion criteria of this review, refer to Table S1.
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3.4. Comparator
Conventional open resection of colon cancer with curative intent acted as a control in
all studies. The only study to compare a laparoscopic intervention to emergency laparotomy
was Tung et al. [11] in colonic obstruction. As with the laparoscopic group, two studies
[14,18] reported on right hemicolectomy and one study [13] reported on left hemicolectomy
in control groups. In the other six studies [11,15–17,19,20], the section of colon resected
reflected tumour location. Toritani et al. [20] reported the use of complete mesocolic




All studies provided data for OS (Table 3). Two studies listed OS as their primary
outcome [11,16], and eight considered it as a secondary outcome [12–15,17–20]. The trials
reported results at various follow-up times. Braga et al. [12,13] only published 5-year
survival results. Conversely, Ishibe et al. [17] only provided 3-year survival results. Six
studies [11,14–16,18,20] reported 5-year OS. The COLOR trial [19] was the only study to
state both 3- and 5-year OS clearly in their paper. After a follow-up of three years, two
studies [17,19] reported OS which was not different (i.e., p > 0.05). At 5-year follow-up,
six studies [11,13–15,18,20] did not find any statistical significance in OS between the
laparoscopic and open resection groups. Meta-analysis revealed no difference between
groups in the survival periods (Figure 2).
3.5.2. Disease-Free Survival
DFS was a primary outcome in three studies [11,15,19] and as a secondary outcome in
seven (Table 4) [12–14,16–18,20]. Chung et al. [14] did not provide any data on this outcome.
Follow-up periods for the reported values varied between studies. Braga et al. [12,13]
provided no data on 3-year DFS. Conversely, Ishibe et al. [17] provided no data regarding
5-year DFS. Five other studies [11,15,16,18,20] reported 5-year DFS in their report without
explicitly stating data on 3-year DFS; in these five studies, we extracted manually the
values for 3-year DFS from Kaplan–Meier curves. Only the COLOR trial [19] stated the
values for both 3- and 5-year DFS directly in their report. Ishibe et al. [17] was the only
study to find no statistically significant difference in 3-year DFS between the two arms
of their study. The COLOR trial [19] suggested that laparoscopic surgery was clinically
non-inferior to open colectomy. At 5-years follow-up, six studies [11–13,15,18,20] found
no significant difference between the laparoscopic and open groups. The results of two
of these studies, Braga et al. [13] and Li et al. [17] excluded patients with stage IV disease.
Meta-analysis revealed no difference between groups in the disease-free periods (Figure 3).
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Table 3. Summary of overall survival at 3 and 5 years and quality of evidence. Data extracted from Kaplan–Meier curves using GetData Graph Digitizer. Excluding patients with stage
IV disease.
Overall Survival 3-Year Follow-Up (%) 5-Year Follow-Up (%) LPS LPT
Study LPS LPT p LPS LPT p Mean SD Patients Mean SD Patients Weight 95% CI Quality of Evidence(GRADE) Comments
Li 2012 83.4 86.1 NA 74.2 75.0 0.835 43.2 99.9 71 58.0 55.6 74 5.2% −14.80 [−41.27,11.67] ⊕⊕Low a,e
There may have been no difference in 5-year OS between
laparoscopic and open surgery.
Braga 2005 NI NI NA 72 66 0.321 13.9 6.6 190 28.6 23.175 201 15.8% −14.70[−18.04,−11.36]
⊕⊕
Low a,e
There may have been no difference in 5-year OS between
laparoscopic and open surgery.
Braga 2010 NI NI NA 61.1 56.5 0.16–0.65according to stage NA NA NA NA NA NA 0 Not estimable
⊕⊕
Low a,e
There may have been no difference in 5-year OS between
laparoscopic and open surgery.
COLOR 2009 81.8 84.2 0.45 73.8 74.2 NI 25.7 27.3 534 31.5 35.2 542 15.7% −5.80 [−9.56,−2.04] ⊕⊕⊕Moderate a
There is probably no difference in 3-year OS after laparoscopic
surgery compared to open surgery.
Ishibe 2017 93.9 93.5 0.901 NI NI NA 19.7 13.4 69 25.3 29.4 63 13.8% −5.60 [−13.52,2.32] ⊕⊕⊕Moderate a
There is probably no difference in 5-year OS after laparoscopic
surgery compared to open surgery.
Tung 2013 71 46 NA 48 27 0.076 29.0 23.9 22 30.3 23.9 13 9.0% −1.30 [−17.69,15.09] ⊕Very Low b,d,e
There may have been no difference in 3-year OS after laparoscopic
compared to open surgery, but the evidence is uncertain.
Toritani 2019 97.1 100.0 NA 93.3 100.0 0.543 55.5 26.2 33 0.0 0.0 33 0 Not estimable ⊕⊕Low a,e
5-year OS after Laparoscopic surgery may not have been
non-inferior to open surgery.
COST 2007 86.8 86.8 NA 76.4 74.6 0.93 50.1 42.76 435 46.2 40.6 428 15.0% 3.90 [−1.66,9.46] ⊕⊕⊕Moderate e
There is probably no difference in 5-year OS after laparoscopic
surgery compared to open surgery.
JCOG404 2017 96 95.8 NA 91.8 90.4 0.073† 53.7 43.3 525 48.8 24.5 520 15.5% 4.90 [0.64,9.16] ⊕Very Low b,d,e
There may have been no difference in 5-year OS after laparoscopic
compared to open surgery, but the evidence is uncertain.
Chung 2007 95 86 NA 83 74 0.90 49.1 44.0 41 28.1 18.0 40 10.0% 21.00 [6.42,35.58] ⊕Very Low a,d,e
There may have been no difference in 5-year OS after laparoscopic
compared to open surgery, but the evidence is uncertain.
GRADE Working Group grades of evidence: ⊕⊕⊕⊕—High quality: further research is very unlikely to change our confidence in the estimate effect. ⊕⊕⊕—Moderate quality: further research is likely to have
an important impact on our confidence in the estimate of effects. ⊕⊕—Low quality: further research is very likely to have an important impact on our confidence in the estimate of effects. ⊕—Very
low quality: we are very uncertain about the estimate. LPS = laparoscopy, LPT = laparotomy. † p-non-inferiority value. a Downgraded one level due to risk of bias or limitations in the detailed design and
implementation. b Downgraded two levels due to risk of bias or limitations in the detailed design and implementation. c Downgraded one level due to unexplained heterogeneity or inconsistency of results.
d Downgraded one level due to indirectness of evidence. e Downgraded one level due to imprecision of results. f Downgraded one level due to high probability of publication bias.
J. Clin. Med. 2021, 10, 4163 8 of 14
J. Clin. Med. 2021, 10, x FOR PEER REVIEW 7 of 16 
 
3.3. Intervention 
All included studies in this review assessed the use of non-robotic, laparoscopic re-
section of the colon with curative intent, with Chung et al. [14] using a hand-assisted tech-
nique. The only study to use a co-intervention was Tung et al., [11] who assessed the effi-
cacy of endoscopically inserted, metal stents prior to laparoscopic resection of cancer ob-
structing the left colon. Nine studies [11–17,19,20] reported the use of adjuvant chemo-
therapy in a proportion of participants. The chemotherapy agent varied between studies 
and included oral 5-fluorouracil derivatives,[16,17] leucovorin,[16[ FOLFOX regimen 
[12,13], fluoropyrimidine [20] and un-specified regimens [11,14,15]. The proportion of pa-
tients receiving chemotherapy was balanced in intervention and comparator groups [19] 
in all studies. Three trials [15,16,20] specified that adjuvant chemotherapy was adminis-
tered in stage III patients. Two studies [14,18] reported only on right laparoscopic hemi-
colectomy and one [13] reported only on left laparoscopic hemicolectomy. The remainder 
of the studies [11,15−17,19,20] included patients with varying tumour locations, which in 
turn governed the resection site. Toritani et al. [20] was the only study to report the use of 
complete mesocolic excision. Lymph node harvesting occurred during laparoscopic sur-
gery in all studies. 
3.4. Comparator 
Conventional open resection of colon cancer with curative intent acted as a control 
in all studies. The only study to compare a laparoscopic intervention to emergency lapa-
rotomy was Tung et al. [11] in colonic obstruction. As with the laparoscopic group, two 
studies [14,18] reported on right hemicolectomy and one study [13] reported on left hemi-
colectomy in control groups. In the other six studies [11,15−17,19,20], the section of colon 
resected reflected tumour location. Toritani et al. [20] reported the use of complete meso-
colic excision in both groups. Lymph node harvesting was performed during open sur-
gery in all studies. 
3.5. Outcomes 
3.5.1. Overall Survival 
All studies provided data for OS (Table 3). Two studies listed OS as their primary 
outcome[11,16], and eight considered it as a secondary outcome [12−15,17−20]. The trials 
reported results at various follow-up times. Braga et al. [12,13] only published 5-year sur-
vival results. Conversely, Ishibe et al. [17] only provided 3-year survival results. Six stud-
ies [11,14−16,18,20] reported 5-year OS. The COLOR trial [19] was the only study to state 
both 3- and 5-year OS clearly in their paper. After a follow-up of three years, two studies 
[17,19] reported OS which was not different (i.e., p > 0.05). At 5-year follow-up, six studies 
[11,13−15,18, 20] did not find any statistical significance in OS between the laparoscopic 
and open resection groups. Meta-analysis revealed no difference between groups in the 
survival periods (Figure 2). 
 
Figure 2. Forest plot of comparison: Mean difference for the overall survival. LPS: laparoscopic approach; LPT: open ap-
proach (laparotomy). 
Figure 2. Forest plot of comparison: Mean difference for the overall survival. LPS: laparoscopic approach; LPT: open
approach (laparotomy).
3.5.3. Meta-Analysis
Studies presented a high within-studies variance. As shown in Figures 2 and 3, at
least 70% of the observed variance between studies is due to real differences in the effect




All studies involved in this review used randomisation to limit baseline differences
between the patient groups. (Table S2) Six [12–15,18–20] used computer-generated lists
to reduce the risk of selection bias. The remaining four [14–17] did not detail how lists
were generated. Five [15–17,19,20] studies employed stratification to minimise imbalance
between the size of the groups. Studies used tumour location or the proposed resection
method as predominant variables. Braga et al., Chung et al., and Li et al., [12–14,18] noted
the use of independent persons to deliver allocation information via sealed envelopes prior
to surgery carries risks of bias [23]. The remaining six studies did not describe allocation
concealment in sufficient detail for comment.
3.6.2. Performance Bias
Due to the surgical nature of the interventions, all studies had considerable perfor-
mance bias, hence a high risk for overall bias. Further, five studies [12,13,16,17,20] noted
adjuvant chemotherapy provision for some participants.
3.6.3. Detection Bias
None of the studies provided information on the assessors used in follow-up. How-
ever, failure to pick up recurrence might have affected DFS.
3.6.4. Attrition Bias
Two studies did not report attrition [14,20]. Five of the remaining papers [12,13,15,17–19]
reported low dropout rates in their studies of 5% or less. Two studies [11,16] reported
dropout rates to be higher than 5%—the JCGOG0404 trial, 16 which reported attrition of
6% and Tung et al., [11] which reported attrition of 27%. Attrition rates of 20% or higher
represent a high risk of attrition bias, and rates between 5% and 20% have a small risk of
bias. [26] Therefore, there is a risk of attrition bias present in these two papers, although the
risk of bias in the JCGOG0404 trial is low. Common reasons for attrition were metastatic
disease at surgery leading to exclusion from the study and patients lost to follow-up.
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Table 4. Summary of disease-free survival at 3 and 5 years and quality of evidence. Data extracted from Kaplan–Meier curves using GetData Graph Digitizer. Excluding patients with
stage IV disease.
Disease-Free Survival 3-Year Follow-Up (%) 5-Year Follow-Up (%) LPS LPT
Study LPS LPT p LPS LPT p Mean SD Patients Mean SD Patients Weight 95% CI Quality ofEvidence (GRADE) Comments
Tung 2013 77 78 NA 52 48 0.63 38.7 28.5 22 45.7 24.8 13 1.7% −7.00 [−24.99,10.99] ⊕Very Low a,d,e
There may have been no difference in 5-year DFS after laparoscopic
compared to open surgery but the evidence is uncertain.
Li 2012 84.3 86.3 NA 82.3 84.1 0.78 14.4 20.1 71 20.6 12.8 74 10.7% −6.20 [−11.71,−0.69] ⊕⊕⊕Moderate e
There is probably no difference in 5-year DFS after laparoscopic
surgery compared to open surgery.
JCOG0404 2017 80.1 82 NA 80 79 NI 17.2 19.2 525 21.84 21.8 520 19.0% −4.64 [−7.13,−2.15] ⊕⊕Low a,e NA
Toritani 2019 90.5 87.2 NA 90.5 87.3 0.752 20.0 3.5 33 20.5 3.2 33 21.5% −0.50 [−2.12,1.12] ⊕Very Low b,d,e
There may have been no difference in 5-year DFS after laparoscopic
compared to open surgery but the evidence is uncertain.
COLOR 2009 74.2 76.2
0.70,
0.030 †
66.5 67.9 NI 20.3 26.1 534 19.1 23.3 542 17.6% 1.20 [−1.76,4.16] ⊕⊕⊕Moderate a
3-year DFS after laparoscopic surgery is probably not non-inferior
to open surgery.
Ishibe 2017 89.6 91.5 0.73 NI NI NA 13.7 13.6 69 11.6 18.8 63 10.4% 2.10 [−3.54,7.74] ⊕Very Low b,d,e
There may have been no difference in 3-year DFS after laparoscopic
compared to open surgery but the evidence is uncertain.
Braga 2005 NI NI NA 64.5 60.2 0.55–0.81according to stage 21.3 26.2 190 18.2 34.34 201 9.7% 3.10 [−2.93,9.13]
⊕⊕
Low a,e
There may have been no difference in 5-year DFS between
laparoscopic and open surgery.
Braga 2010 NI NI NA 63 63 0.405 NA NA NA NA NA NA 0 Not estimable ⊕⊕Low a,e
There may have been no difference in 5-year DFS between
laparoscopic and open surgery.
COST 2007 80.4 79.2 NA 69.2 68.4 0.94 36.4 47.9 435 32.0 44.0 428 9.5% 4.40 [−1.73,10.53] ⊕⊕⊕Moderate a
There is probably no difference in 5-year DFS after laparoscopic
surgery compared to open surgery.
Chung 2007 NI NI NA NI NI NA NA NA NA NA NA NA 0 Not estimable ⊕⊕Low a,e N/A
GRADE Working Group grades of evidence: ⊕⊕⊕⊕—High quality: further research is very unlikely to change our confidence in the estimate effect. ⊕⊕⊕—Moderate quality: further research is likely to have
an important impact on our confidence in the estimate of effects. ⊕⊕—Low quality: further research is very likely to have an important impact on our confidence in the estimate of effects. ⊕—Very
low quality: we are very uncertain about the estimate. LPS = laparoscopy, LPT = laparotomy. † p-non-inferiority value. a Downgraded one level due to risk of bias or limitations in the detailed design and
implementation. b Downgraded two levels due to risk of bias or limitations in the detailed design and implementation. c Downgraded one level due to unexplained heterogeneity or inconsistency of results. d
Downgraded one level due to indirectness of evidence. e Downgraded one level due to imprecision of results. f Downgraded one level due to high probability of publication bias.
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3.6.5. Reporting Bias
No paper reported any conflicts of interest. Seven reported no external funding.
The COST trial received a number of grants from the National Cancer Institute [15] and
the COLOR trial received funding from Ethicon Endo-surgery and the Swedish Cancer
Foundation [19]. Neither corporation influenced initiation, design or any other aspect of
the study.
4. Discussion
We evaluated OS, DFS and recurrence kinetics after laparoscopic vs. open surgical
approach for colon cancer resection. There is probably no difference in these outcomes
(moderate to very low level of certainty). As there is uncertain evidence about the differ-
ences in the inflammatory response after laparoscopy vs. laparotomy for colon cancer,
we cannot formally conclude on the absence of effect of inflammatory processes on the
outcome. However, we can reasonably conclude that the effect of the surgical approach on
the inflammatory response, if any, is probably not sufficient to influence these outcomes.
Increased inflammation or immunosuppression caused by surgical technique may
favour cancer proliferation after surgery, depending on the type of inflammatory mediators
produced [27,28]. However most studies come from often small laboratory experiments or
trials, while what happens in the human body is incredibly more complex [29]. Here, we
evaluated OS and DFS after laparoscopic vs. open approach for colon cancer resection.
All included papers discussed these outcomes. Four trials [11,15,16,19] had either-
or both outcomes as their primary endpoint, and six [12–14,17,18,20] had them as part
of their secondary endpoint. Both outcomes were further split into 3-year OS/DFS, and
5-year OS/DFS.
Due to colon cancer’s potential to progress into a higher-grade cancer, it was diffi-
cult for the patients recruited to have open surgery or laparoscopic surgery as their sole
intervention throughout the study. The JCOG0404 trial [16] randomly assigned 1057 pa-
tients at the beginning to two treatment arms: laparoscopic resection and open resection.
However, of the 520 that had open surgery, 174 (33.5%) had adjuvant chemotherapy, and
of the 525 that had laparoscopic surgery, 199 (37.9%) underwent adjuvant chemotherapy.
These patients, however, were included with patients that did not undergo this additional
treatment. Thus, as the adjuvant chemotherapy could have been a confounding factor, data
for survival outcomes may have been affected. This confounder was also present in the
trial by Braga et al., [12] where adjuvant chemotherapy was given to 118 (62.1%) patients
in the laparoscopic surgery arm, and 124 (61.6%) patients in the open surgery arm, the
COLOR trial [19] and Toritani et al. [20]. In addition, the majority of papers [12,13,16,17,20]
did not report on the chemotherapy regime or length of treatment. No papers mentioned
the dosage of chemotherapy given to the patients. These factors may have greatly affected
outcomes but also open a new avenue of research on the need to consider the perioper-
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ative management (and treatments) of cancer as a whole in patients (before, during and
after surgery).
There were some inconsistencies regarding patient cohort characteristics across the
trials. Ishibe et al. [17] recruited patients >75 years of age, Toritani et al. [20] recruited
patients >20 years of age, the JCOG0404 trial [16] recruited patients from 20–75 years old,
Tung et al. [11] did not mention the age group of their patients, and the other trials recruited
patients >18 years. As Ishibe et al. [17] had produced data from a patient-population of the
elderly, it may be inappropriate to compare this set of data to data from other trials studying
patients of a wider age range. The presence of co-morbidities is more likely among elderly
patients, which will influence the data on OS and DFS rates. Age, and potentially frailty,
is particularly relevant to consider in the perioperative context but insufficient, and the
limited sample size here precludes any specific conclusion on that [30–33].
4.1. Quality of Evidence (GRADE)
The quality of evidence ranged from moderate to very low across the studies included
in this review. All studies, excluding Li et al., [18] were downgraded by at least one level
as they were deemed high risk of bias according to the Cochrane RoB 2.0 tool (Cochrane
Collaboration, Copenhagen, Denmark) [34]. This was mainly due to a lack of blinding
in the surgical setting of the trials. Ishibe et al. [17] and Toritani et al. [20] were marked
down by a further level due to risk of bias in the measurement of outcomes. The quality of
evidence from Ishibe et al. [17] and Tung et al. [11] was further lowered due to indirectness
of the population (elderly participants) and intervention (co-intervention with endoscopic
stenting) respectively. Imprecision due to a lack of power towards survival outcomes
lowered the quality of evidence in all six superiority trials and the JCOG0404 trial [16]. In
the superiority trials, this was due to assessment of these outcomes as secondary outcomes.
The JCOG0404 trial [16] authors aimed to power their trial to 5-year OS, but they failed to
accrue an adequate number of participants to reach their intended power.
The meta-analysis carried out in this review included RCTs in the present systematic
review, in particular, the COLOR trial [19]. Although this trial could not statistically prove
non-inferiority, when combined with other studies in meta-analysis, no statistically signifi-
cant difference between laparoscopic surgery and open surgery was seen. We recommend
an updated meta-analysis looking at 3- and 5-year survival so that an assessment of effect
sizes can be carried out with the inclusion of studies published since Di et al. [35].
4.2. Limitations
As mentioned, the quality of multiple studies used in this review were downgraded
due to lack of blinding, concerns about outcome measurement, and indirectness of popula-
tion and intervention. This brings to question the validity of the data analysed, as some
may be inaccurate.
Data that were not directly reported in some studies, such as 3-year survival, were
extracted from Kaplan–Meier graphs. The limitation of this is that p-values have not been
calculated. However, it is reasonable to extrapolate 5-year confidence intervals to 3-year
data, which would make these data more robust.
There were several studies in which data might possibly be unreliable due to its small
sample size. Chung et al., [14] Tung et al., [11] and Toritani et al. [20] reported that the num-
ber of patients they had recruited and randomised into the trial was
81, 48 and 66 respectively. Their sample sizes are significantly smaller than other tri-
als analysed in this systematic review (COLOR trial [19]—1248 patients, and JCOG040
trial [16]—1057 patients). Trials with small sample sizes risk false-positive results and
over-estimation of differences in outcomes [36–39]. In this case, any difference in out-
comes between the laparoscopic and open surgery groups might appear to be overstated.
Overall, this warrants further studies to reduce uncertainty. Other future human stud-
ies could include, for example, better staging of colon cancer patients allowing for more
accurate stratification.
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5. Conclusions
This meta-analysis shows that laparoscopic surgery appears to have a similar outcome,
and specifically similar recurrence dynamics, when compared to open surgery for the
intended curative treatment of colon cancer in the adult population, in relations to OS and
DFS at both three and five years. Future research is needed on other cancers or in patients
with different profiles (metastatic diseases, specific conditions like advanced age or frailty)
to study whether the same conclusion can be reached. Finally, we suggest considering as a
whole the perioperative care and treatments of the cancer patients.
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